Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The gut microbiota-intestinal epithelium-mucosal immune system axis is a tripartite functional unit that maintains intestinal homeostasis and systemic health (Belkaid & Hand, 2014, Science). The gut microbiota provides essential metabolic signals, such as short-chain fatty acids, which support the energy needs of the intestinal epithelium and promote the differentiation of regulatory T cells (Tregs) (Arpaia et al., 2013, Nature). The intestinal epithelium serves as a selective barrier, utilizing tight junctions and mucus layers to prevent the translocation of luminal contents into the underlying lamina propria (Okumura & Takeda, 2017, Nature Reviews Immunology). Within the mucosal immune system, specialized cells like dendritic cells and M cells sample antigens to coordinate appropriate immune responses, balancing tolerance toward commensals with defense against pathogens (Mowat & Agace, 2014, Nature Reviews Immunology). Disruptions in this axis, often termed dysbiosis or "leaky gut," are linked to the pathogenesis of inflammatory bowel disease, obesity, and various autoimmune conditions (Levy et al., 2017, Nature Reviews Immunology). Pharmacological and dietary interventions, including probiotics, fecal transplants, and biologics targeting specific cytokines, aim to recalibrate this system to restore health (Cunningham et al., 2021, Nature Reviews Gastroenterology & Hepatology).
Modulation of microbial composition, enhancement of epithelial barrier integrity, and regulation of mucosal inflammatory signaling.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gut microbiota-intestinal epithelium-mucosal immune system axis (GIM axis).